Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor

被引:38
作者
Cocklin, Simon
Gopi, Hosahudya
Querido, Bianca
Nimmagadda, Manideepthi
Kuriakose, Syna
Cicala, Claudia
Ajith, Sandya
Baxter, Sabine
Arthos, James
Martin-Garcia, Julio
Chaiken, Irwin A.
机构
[1] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA
[2] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Ctr Mol Virol & Neuroimmunol,Inst Mol Med & Infec, Philadelphia, PA 19102 USA
[3] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.01778-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The AIDS epidemic continues to spread at an alarming rate worldwide, especially in developing countries. One approach to solving this problem is the generation of anti-human immunodeficiency virus (HIV) compounds with inhibition spectra broad enough to include globally prevailing forms of the virus. We have examined the HIV type 1 (HIV-1) envelope specificity of a recently identified entry inhibitor candidate, UNG-105, using surface plasmon resonance spectroscopy and pseudovirus inhibition assays. The combined results suggest that the HNG-105 molecule may be effective across the HIV-1 subtypes, and they highlight its potential as a lead for developing therapeutic and microbicidal agents to help combat the spread of AIDS.
引用
收藏
页码:3645 / 3648
页数:4
相关论文
共 34 条
[1]   The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates [J].
Ariën, KK ;
Abraha, A ;
Quiñones-Mateu, ME ;
Kestens, L ;
Vanham, G ;
Arts, EJ .
JOURNAL OF VIROLOGY, 2005, 79 (14) :8979-8990
[2]   Inhibiting HIV-1 entry with fusion inhibitors [J].
Baldwin, CE ;
Sanders, RW ;
Berkhout, B .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (17) :1633-1642
[3]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[4]   Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions [J].
Biorn, AC ;
Cocklin, S ;
Madani, N ;
Si, ZH ;
Ivanovic, T ;
Samanen, J ;
Van Ryk, DI ;
Pantophlet, R ;
Burton, DR ;
Freire, E ;
Sodroski, J ;
Chaiken, IM .
BIOCHEMISTRY, 2004, 43 (07) :1928-1938
[5]  
Borkow G., 2005, Current Drug Targets - Infectious Disorders, V5, P3, DOI 10.2174/1568005053174645
[6]   HIV-1 entry and how to block it [J].
Brelot, A ;
Alizon, M .
AIDS, 2001, 15 :S3-S11
[7]   The appealing story of HIV entry inhibitors - From discovery of biological mechanisms to drug development [J].
Castagna, A ;
Biswas, P ;
Beretta, A ;
Lazzarin, A .
DRUGS, 2005, 65 (07) :879-904
[8]   Structure of an unliganded simian immunodeficiency virus gp120 core [J].
Chen, B ;
Vogan, EM ;
Gong, HY ;
Skehel, JJ ;
Wiley, DC ;
Harrison, SC .
NATURE, 2005, 433 (7028) :834-841
[9]   SEQUENCE-ANALYSIS AND ACUTE PATHOGENICITY OF MOLECULARLY CLONED SIVSMM-PBJ14 [J].
DEWHURST, S ;
EMBRETSON, JE ;
ANDERSON, DC ;
MULLINS, JI ;
FULTZ, PN .
NATURE, 1990, 345 (6276) :636-640
[10]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732